UVA Cancer Center, an NCI Comprehensive Cancer Center | Strategic Alliance Partners

April 18, 2024

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

March 25, 2024

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

July 06, 2023

Paola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.

June 29, 2023

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

April 04, 2023

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Marilyn Huang, MD, MS

March 22, 2023

Robert Dreicer, MD, discusses the use of triplet therapy in the first-line management of de novo metastatic prostate cancer.

April 20, 2022

March 15, 2022

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

April 28, 2021

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

April 09, 2021

Robert Dreicer, MD, discusses the optimal use of checkpoint inhibitors in urothelial carcinoma.

March 03, 2021

December 04, 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

November 25, 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

November 19, 2020

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

November 19, 2020

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

November 17, 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

April 21, 2020

Although the standard of care for muscle-invasive bladder cancer is well established, not enough patients are being treated with curative intent.

February 08, 2020

Linda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.

January 29, 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

August 29, 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.